Methylenedioxypyrovalerone ("Bath Salts"),Related Death: Case Report and Review of the Literature,

Journal of Forensic Sciences

Volumn 58, Issue 6, 2013, Pages 1654-1659

  Kesha, Kilak ^a   Boggs, Cassie L ^a   Ripple, Mary G ^a   Allan, Carol H ^a   Levine, Barry ^a   Jufer Phipps, Rebecca ^a   Doyon, Suzanne ^b   Chi, Paolin ^c   Fowler, David R ^a  

^a OFFICE OF THE CHIEF MEDICAL EXAMINER   (United States)

^b Maryland Poison Center   (United States)

^c Wayne State Medical Center   (United States)

Author keywords

Bath salts; Designer drugs; Forensic science; Hyperthermia; Methylenedioxypyrovalerone; Recreational drugs; Synthetic cathinones

Indexed keywords

1,3 BENZODIOXOLE DERIVATIVE; 3,4 METHYLENEDIOXYPYROVALERONE; 3,4-METHYLENEDIOXYPYROVALERONE; DESIGNER DRUG; METHYLENEDIOXYPYROVALERONE; PSYCHOTROPIC AGENT; PYRROLIDINE DERIVATIVE;

ADULT; ARTICLE; BATH SALTS; BLOOD; CASE REPORT; CHEMICALLY INDUCED DISORDER; DELIRIUM; FATALITY; FEVER; FORENSIC SCIENCE; FORENSIC TOXICOLOGY; HEART VENTRICLE TACHYCARDIA; HUMAN; HYPERTHERMIA; MALE; RECREATIONAL DRUGS; SYNTHETIC CATHINONES;

BATH SALTS; DESIGNER DRUGS; FORENSIC SCIENCE; HYPERTHERMIA; METHYLENEDIOXYPYROVALERONE; RECREATIONAL DRUGS; SYNTHETIC CATHINONES;

ADULT; BENZODIOXOLES; DELIRIUM; DESIGNER DRUGS; FATAL OUTCOME; FEVER; FORENSIC TOXICOLOGY; HUMANS; MALE; PSYCHOTROPIC DRUGS; PYRROLIDINES; TACHYCARDIA, VENTRICULAR;

EID: 84886746642     PISSN: 00221198     EISSN: 15564029     Source Type: Journal    
DOI: 10.1111/1556-4029.12202     Document Type: Article

References (45)

1. Hill SL, Thomas SH. Clinical toxicology of newer recreational drugs. Clin Toxicol (Phila) 2011;49(8):705-19. Review. Erratum in: Clin Toxicol (Phila) 2011;49(9):880.
2. The European Monitoring Centre for Drugs and Drug Addiction (EMCDDA). Drug profiles: synthetic cathinones. Lisbon, Portugal: EMCDDA. updated September 15, 2011. http://www.emcdda.europa.eu/publications/drug-profiles/synthetic-cathinones (accessed January 10, 2012).
3. Prosser JM, Nelson LS. The toxicology of bath salts: a review of synthetic cathinones. J Med Toxicol 2012;8(1):33-42.
4. Brandt SD, Freeman S, Sumnall HR, Measham F, Cole J. Analysis of NRG 'legal highs' in the UK: identification and formation of novel cathinones. Drug Test Anal 2011;3(9):569-75.
5. Hunterdon Drug Awareness Program (HDAP). Comprehensive drug information on "bath salts" (MDPV, Mephedrone). Flemington, NJ: HDAP, updated December 28, 2011; http://www.hdap.org/mdpv.html (accessed January 9, 2012).
6. Benzie F, Hekman K, Cameron L, Wade DR, Miller C, Smolinske S, et al. Emergency department visits after use of a drug sold as "bath salts"-Michigan, November 13, 2010-March 31, 2011. MMWR Morb Mortal Wkly Rep 2011;19:624-47.
7. Drug Enforcement Administration/Office of Diversion Control/Drug & Chemical Evaluation Section. 3, 4-Methylenedioxypyrovalerone (MDPV); http://www.DEAdiversion.usdoj.gov/drugs_concern/mdpv.pdf (accessed July 20, 2011 and January 10, 2012).
8. Wehrman J. U.S. Poison Centers raise alarm about toxic substance marketed as bath salts [press release]. Alexandria, VA: American Association of Poison Control Centers (AAPCC), December 21, 2010.
9. American Association of Poison Control Centers (AAPCC). Bath salts data. Alexandria, VA: AAPCC, updated January 5, 2012; http://www.aapcc.org/dnn/Portals/0/Bath%20Salts%20Data%20for%20Website%201.5.2012.pdf. (accessed January 9, 2012).
10. Bronstein AC, Spyker DA, Cantilena LR Jr, Green JL, Rumack BH, Dart RC. 2010 Annual report of the American Association of Poison Control Centers' National Poison Data System (NPDS): 28th annual report. Clin Toxicol (Phila) 2011;49(10):910-41.
11. Iversen L. Consideration of the cathinones. London, UK: Advisory Council on the Misuse of Drugs (ACMD); 2010 March Report.
12. National Conference of State Legislation (NCSL). Substituted cathinones legislation. Washington, DC: NCSL, updated October 24, 2011; http://www.ncsl.org/?TabId=22432 (accessed January 10, 2012).
13. North Yorkshire Police. MDPV. Northallerton, England: North Yorkshire Police, February 2011; http://www.northyorkshire.police.uk/mdpv (accessed January 10, 2012).
14. Yohannan JC, Bozenko JS Jr. The characterization of 3, 4-Methylenedioxypyrovalerone (MDPV). US-DOJ-43 Special Testing Research Laboratory. Microgram J 2010;7(1):12-5.
15. Spiller HA, Ryan ML, Weston RG, Jansen J. Clinical experience with and analytical confirmation of "bath salts" and "legal highs" (synthetic cathinones) in the United States. Clin Toxicol 2011;49(6):499-505.
16. Antonowicz JL, Metzger AK, Ramanujam SL. Paranoid psychosis induced by consumption of methylenedioxypyrovalerone: two cases. Gen Hosp Psychiatry 2011;33(6):640.e5-6.
17. Kriikku P, Wilhelm L, Schwarz O, Rintatalo J. New designer drug of abuse: 3, 4-Methylenedioxypyrovalerone (MDPV). Findings from apprehended drivers in Finland. Forensic Sci Int 2011;210(1-3):195-200.
18. Coppola M, Mondola R. 3, 4-methylenedioxypyrovalerone (MDPV): chemistry, pharmacology and toxicology of a new designer drug of abuse marketed online. Toxicol Lett 2012;208(1):12-5.
19. Kasick DP, McKnight CA, Klisovic E. "Bath salt" ingestion leading to severe intoxication delirium: two cases and a brief review of the emergence of mephedrone use. Am J Drug Alcohol Abuse 2012;38(2):176-80.
20. Maskell PD, De Paoli G, Seneviratne C, Pounder DJ. Mephedrone (4-methylmethcathinone)-related deaths. J Anal Toxicol 2011;35(3):188-91.
21. Regan L, Mitchelson M, Macdonald C. Mephedrone toxicity in a Scottish emergency department. Emerg Med J 2011;28(12):1055-8.
22. Wood DM, Davies S, Greene SL, Button J, Holt DW, Ramsey J, et al. Case series of individuals with analytically confirmed acute mephedrone toxicity. Clin Toxicol (Phila) 2010;48(9):924-7.
23. James D, Adams RD, Spears R, Cooper G, Lupton DJ, Thompson JP, et al. Clinical characteristics of mephedrone toxicity reported to the U.K. National Poisons Information Service. Emerg Med J 2011;28(8):686-9.
24. Strano-Rossi S, Cadwallader AB, de la Torre X, Botrè F. Toxicological determination and in vitro metabolism of the designer drug methylenedioxypyrovalerone (MDPV) by gas chromatography/mass spectrometry and liquid chromatography/quadrupole time-of-flight mass spectrometry. Rapid Commun Mass Spectrom 2010;24(18):2706-14.
25. Ojanperä IA, Heikman PK, Rasanen IJ. Urine analysis of 3, 4-methylenedioxypyrovalerone in opioid-dependent patients by gas chromatography-mass spectrometry. Ther Drug Monit 2011;33(2):257-63.
26. Quan D, Haase D, Levitan R. Legal drugs of abuse. Emerg Med Reports 2011;32(20):237-48.
27. Expert Committee on Drug Dependence (ECDD). Assessment of khat (Catha edulis Forsk). Geneva, Switzerland: World Health Organization, 2006March 28-31. Report No.: 34th ECDD 2006/4.4;1-25; http://www.who.int/medicines/areas/quality_safety/4.4KhatCritReview.pdf (accessed January 10, 2012).
28. Gardos G, Cole JO. Evaluation of pyrovalerone in chronically fatigued volunteers. Curr Ther Res Clin Exp 1971;13(10):631-5.
29. Goldberg J, Gardos G, Cole JO. A controlled evaluation of pyrovalerone in chronically fatigued volunteers. Int Pharmacopsychiatry 1973;8(1):60-9.
30. Fuwa T, Fukumori N, Tanaka T, Kubo Y, Ogaga A, Uehara S, et al. Microdialysis study of drugs on the central nervous system. Changes of dopamine levels in mice striatum after oral administration of methylenedioxypyrovalerone. Tokyo-to Kenko Anzen Kenkyu Senta Kenkyu Nenpo 2007;58:287-92.
31. Meltzer PC, Butler D, Deschamps JR, Madras BK. 1-(4-Methylphenyl)-2-pyrrolidin-1-yl-pentan-1-one (Pyrovalerone) analogs. A promising class of monoamine uptake inhibitors. J Med Chem 2006;49(4):1420-32.
32. Fuwa T, Kodama T, Honda Y, Tanaka T, Kubo Y, Ohashi N, et al. Influence of methylenedioxypyrovalerone on central nervous system using microdialysis method. Chem Bio Integrated Management 2009;5:62-72.
33. The vaults of Erowid; http://www.erowid.org/chemicals/mdpv/ (accessed January 12, 2012).
34. Penders TM, Gestring R. Hallucinatory delirium following use of MDPV: "bath salts". Gen Hosp Psychiatry 2011;33(5):525-6.
35. Ross EA, Watson M, Goldberger B. "Bath salts" intoxication. N Engl J Med 2011;365(10):967-8.
36. Spiller HA, Ryan ML, Weston RG, Jansen J, Arnold T. Case series of bath salts exposures with blood and urine quantification. Clin Toxicol 2011;49(6):523. (abstract).
37. Michigan Poison Control. "Bath salts" health care provider fact sheet. Published February 2011, updated Sept 2011; http://www.michigan.gov/documents/mdch/Bath_Salts_FAQ_Health_Care_Providers_344881_7.pdf. (accessed July 7, 2011).
38. Durham M. Ivory wave: the next mephedrone? Emerg Med J 2011;28(12):1059-60.
39. Adebamiro A, Perazella MA. Recurrent acute kidney injury following bath salts intoxication. Am J Kidney Dis 2012;59(2):273-5.
40. Russo R, Marks N, Morris K, King H, Gelvin A, Rooney R. Life-threatening necrotizing fasciitis due to 'bath salts' injection. Orthopedics 2012;35(1):e124-7.
41. Brandt SD, Sumnall HR, Measham F, Cole J. Analyses of second-generation 'legal highs' in the UK: initial findings. Drug Test Anal 2010;2(8):377-82.
42. 3, 4-Methylenedioxypyrovalerone (MDPV) [press release]. Drug Enforcement Administration/Office of Diversion Control/Drug & Chemical Evaluation Section. October 21, 2011.
43. Drug Enforcement Administration, Department of Justice. Schedules of controlled substances: temporary placement of three synthetic cathinones in Schedule 1. Final Order. Fed Regist 2011;76(204):65371-5.
44. Bell C, George C, Kicman AT, Traynor A. Development of a rapid LC-MS/MS method for direct urinalysis of designer drugs. Drug Test Anal 2011;3(7-8):496-504.
45. Meyer MR, Du P, Schuster F, Maurer HH. Studies on the metabolism of the α-pyrrolidinophenone designer drug methylenedioxypyrovalerone (MDPV) in rat and human urine and human liver microsomes using GC-MS and LC-high-resolution MS and its detectability in urine by GC-MS. J Mass Spectrom 2010;45(12):1426-42.